JFG
LCTX icon

Jefferies Financial Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Jefferies Financial Group’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$69.8K Sell
44,192
-14,898
-25% -$25.1K ﹤0.01% 1628
2025
Q4 		$98.7K Sell
59,090
-3,110
-5% -$5.38K ﹤0.01% 1704
2025
Q3 		$105K Buy
+62,200
New +$73.6K ﹤0.01% 1336
2023
Q2 		– Sell
-23,998
Closed -$36K – 1870
2023
Q1 		$36K Buy
+23,998
New +$33.5K ﹤0.01% 1512

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jefferies Financial Group's LCTX Position: Q1 2026 in Review

Jefferies Financial Group reduced its Lineage Cell Therapeutics (LCTX) stake by 25% in Q1 2026, selling an estimated $25.1K and leaving 44,192 shares worth $69.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1628.

Jefferies Financial Group first reported a position in LCTX in Q1 2023 and has held it in 4 quarters since. The position peaked at $105K in Q3 2025. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

  • Jefferies Financial Group held 44,192 shares of Lineage Cell Therapeutics worth $69.8K as of Q1 2026.
  • Jefferies Financial Group sold 14,898 Lineage Cell Therapeutics shares in Q1 2026, an estimated $25.1K.
  • Lineage Cell Therapeutics made up ﹤0.01% of Jefferies Financial Group's portfolio in Q1 2026, its #1628 holding.
  • Jefferies Financial Group first reported a position in Lineage Cell Therapeutics in Q1 2023 and has held it in 4 quarters since.
  • Jefferies Financial Group's Lineage Cell Therapeutics position peaked at $105K in Q3 2025.
  • 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.